Table of Contents Author Guidelines Submit a Manuscript
E-Journal of Chemistry
Volume 5, Issue 4, Pages 706-712

HPTLC Method for Simultaneous Determination of Lopinavir and Ritonavir in Capsule Dosage Form

A. V. Sulebhavikar,1 U. D. Pawar,1,2 K. V. Mangoankar,1,2 and N. D. Prabhu-Navelkar1,2

1Department of Chemistry, K. J. Somaiya Senior College of Science and Commerce, Vidyanagar, Vidyavihar, Mumbai-400077, India
2Department of Chemistry, Mithibai College of Arts, Chaun Institute of Science & Amrutben Jivanlal College of Commerce and Economics, Vile Parle (W), Mumbai400 056, India

Received 13 October 2007; Revised 14 December 2007; Accepted 21 January 2008

Copyright © 2008 Hindawi Publishing Corporation. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


A rapid and simple high performance thin layer chromatography (HPTLC) method with densitometry at λ=263 nm was developed and validated for simultaneous determination of lopinavir and ritonavir from pharmaceutical preparation. Separation was performed on aluminum-backed silica gel 60F254 HPTLC plates as stationary phase and using a mobile phase comprising of toluene, ethyl acetate, methanol and glacial acetic acid, in the volume ratio of 7.0:2.0:0.5:0.5 (v/v) respectively. After development, plates were observed under UV light. The detector response was linear in the range of 6.67 to 20.00 µg/spot and 1.67 to 5.00 µg/spot for lopinavir and ritonavir respectively. The validated lowest limit of detection was 21.00 ng/spot and 5.10 ng/spot whereas lowest limit of quantification was 7.00 ng/spot and 21.00 ng/spot for lopinavir and ritonavir respectively. The percentage assay of lopinavir and ritonavir was found between 98.23 to 102.28% and 98.03 to 103.50% respectively. The described method has the advantage of being rapid and easy. Hence it can be applied for routine quality control analysis of lopinavir and ritonavir from pharmaceutical preparation and stability studies.